Physician profile
David E Vickery
NPI 1790707867
$1,928.84
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $304.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $260.84 | 2019-2020 | |
| Novo Nordisk INC | $203.26 | 2019-2020 | |
| Glaxosmithkline, LLC. | $200.87 | 2019-2020 | |
| Pfizer INC. | $170.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $161.06 | 2019-2020 | |
| Lilly USA, LLC | $159.94 | 2019-2020 | |
| Astellas Pharma US INC | $143.20 | 2019-2020 | |
| Amgen INC. | $120.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $117.55 | 2019 | |
| Amarin Pharma, INC. | $93.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.80 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.62 | 2019 | |
| Allergan, INC. | $34.31 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $27.89 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Circassia INC. | $25.47 | 2019 | |
| Nabriva Therapeutics, Plc | $16.30 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.61 | 2019 | |
| Boston Scientific Corporation | $11.50 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vickery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.